698 results about "Central nervous system" patented technology

The invention discloses a self-adaptive music intervention system based on multi-modal physiological feedback, and belongs to the technical field of monitoring and intervention of emotional states, the self-adaptive music intervention system comprises a multi-modal emotional state evaluation module and a self-adaptive music intervention module, the multi-modal emotional state evaluation module acquires multi-modal physiological information of a user, and the self-adaptive music intervention module performs music intervention on the multi-modal emotional state evaluation module; feature extraction and fusion are carried out on the multi-modal data, and the emotional state is evaluated according to the fused data; and the adaptive music intervention module generates music features matched with the current emotion according to the evaluated emotion state, the music features and preference data of the user, and selects music according to the music features to intervene the user. By the adoption of the method, the wearable forehead lobe three-lead electroencephalogram equipment and the intelligent bracelet are combined, physiological signals of the central nervous system and the autonomic nervous system are collected and analyzed in real time, music intervention is automatically adjusted, a personalized emotion adjusting scheme free of side effects is provided, and a closed-loop mental state regulation and control mechanism is formed.

The present disclosure relates generally to methods for treating or preventing central nervous system (CNS) metastases with a KRAS inhibitor, and more specifically to treating CNS metastases with a pyridopyrimidine derivative.

The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.

The disclosure provides technologies that permit detection and / or characterization of brain biomarkers (e.g., disease-associated biomarkers) in non-CNS samples, including by liquid biopsy (e.g., blood, serum, etc.). Among other things, the present disclosure demonstrates that ultrasound opening of the blood brain barrier can achieve detectable increases in brain-derived materials (e.g., brain-derived proteins, neuron-derived extracellular vesicles, and / or cell-free DNA) in readily-sampled systemic liquids.

Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.

The invention provides a neurosteroid derivative solid dispersion, a preparation method and application thereof, and a medicine containing a hot-melt extrusion solid dispersion, and belongs to the technical field of pharmacy. The preparation method comprises the following steps: carrying out melt extrusion on a raw material mixture at 125-160 DEG C to obtain the neurosteroid derivative solid dispersion, the mixed material comprises an active component, a plasticizer and a carrier material in a mass ratio of 10: (1-15): (10-90); the active component comprises at least one of a neurosteroid derivative (with a structure as shown in a formula 1), an isomer, a solvate and a pharmaceutically acceptable salt thereof; the plasticizer is selected from one or more of polyethylene glycol, poloxamer and Tween, and the average molecular weight of the polyethylene glycol is 1t; 6000, 6000; active components in the neurosteroid derivative solid dispersion exist in an amorphous state. The neurosteroid derivative in the neurosteroid derivative solid dispersion disclosed by the invention has relatively high oral bioavailability. # imgabs0 #

There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin receptor or monoamine transporter, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin receptor or monoamine transporter, such as inflammation, central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.

Provided herein are methods for treating cancer comprising intranasal administration of an oncolytic virus or an oncolytic virus-based vector, comprised in a mesenchymal stem cell (MSC), an MSC-derived EV, or in an MSC-derived bioxome. Further, the MSCs, MSC-derived EVs, or MSC-derived bioxomes disclosed herein may be used for treating a central nervous system (CNS) related disorder.

The present invention discloses compounds, compositions, methods for modulating central nervous system activity, methods for treating inflammatory or metabolic disorders, and methods for treating central nervous system disorders, such as depression, anxiety, and trauma- and stressor-related disorders, comprising the indolizines having the structures disclosed herein.

An RNAi agent and composition for inhibiting the expression of transthyretin (TTR), which can be used for treating and / or preventing ATTR-related diseases comprising ATTR-PN (transthyretin amyloidosis polyneuropathy), ATTR-CM (transthyretin amyloidosis cardiomyopathy), senile systemic amyloidosis diseases, and leptomeningeal / central nervous system amyloidosis diseases.

The invention discloses a coenzyme Q10-containing medicine for improving heart activity and a preparation method thereof, and particularly belongs to the technical field of biological medicines. The medicine comprises functional components and auxiliary materials, wherein the functional components comprise a cactus extract, a calligonum mongolicum extract, an astragalus membranaceus extract, a sea-buckthorn extract and coenzyme Q10; the hypoxia survival time and the load-bearing swimming time of mice can be remarkably prolonged through low, medium and high dose groups of the medicine for improving the heart vitality, the requirement of fatigue caused by high labor intensity for oxygen is further met by enhancing the immunity of the organism, supply of nutrient substances to the brain, the heart, the bones and the muscles of the organism is enhanced, and the effect of improving the heart vitality is achieved. The composition can regulate the activity of central nervous system, promote the normal operation of the body circulation system, relieve and eliminate fatigue and damage to the body caused by fatigue and chronic fatigue, and quickly recover physical strength.

The invention relates to double-encapsulated lipid nanoparticles entering brain through nose and a preparation method and application thereof, the double-encapsulated lipid nanoparticles comprise lipid nanoparticles, drugs in the lipid nanoparticles and rana odorata lectin coupled to the surfaces of the lipid nanoparticles, and the drugs comprise hydrophilic drugs and hydrophobic drugs. According to the invention, the rana odorata lectin and the lipid nanoparticles are coupled, and the rana odorata lectin can be specifically combined with L-fucose residues expressed by olfactory epithelial cells, so that the adhesion of the lipid nanoparticles to olfactory epithelium during nasal administration is enhanced, and the brain entering efficiency of the lipid nanoparticles is finally improved. After entering the brain, the lipid nanoparticles respond to diseased regions with high active oxygen content so as to release drugs. In addition, double-drug encapsulation can target different pathogenesis of central nervous system diseases, and the limitation that a traditional treatment drug is single in action target is improved.

Sublingual or buccal dosage forms comprise at least one antioxidant compound, such as N-acetyl cysteine (NAC), or a pharmaceutically acceptable salt thereof. The sublingual or buccal dosage forms are administered for treating central nervous system (CNS) disorders, such as traumatic brain injury or stroke.

The invention belongs to the technical field of exosome modification, and particularly relates to an exosome modification method for connecting a target protein to the surface of an exosome by utilizing NHS-PEG-NHS to achieve a targeting or treatment effect, and application of the exosome modification method in targeted central nervous system demyelination disease treatment. In particular to a technology for modifying an exosome to enable the exosome to have targeting property and a preparation method of the exosome. NHS-PEG-NHS is used as a connecting substance, and protein, polypeptide and substances with primary amine groups on the surface can be connected to the surface of an exosome membrane. The modified exosome can load drugs and can be accurately delivered to tissues expressing specific proteins or polypeptides through oral administration, so that the bioavailability and the treatment effect of the drugs are remarkably improved. Taking the NG2 antibody modified cow milk exosome as an example, the NG2 antibody is connected to the surface of the cow milk exosome to target the central demyelination focus area, so that the effective therapeutic dose of the drug in the central focus area is achieved through oral delivery.

The invention discloses a pharmaceutical composition which comprises anisodine or salt thereof and 2-borneol or related substances thereof. The pharmaceutical composition provided by the invention has a synergistic effect in treatment of cardia-cerebrovascular diseases, especially central nervous diseases such as acute ischemic stroke, can effectively improve the effect of patients with cerebrovascular diseases, especially central diseases such as acute ischemic stroke, and improves the quality of life.

A rehabilitation evaluation system for a patient with central nervous system dysfunction comprises the following steps of S1, collecting videos, motion data and pressure data of a user through a data collection layer, S2, uploading the video data to an edge computing server, performing preliminary posture estimation, and S3, performing rehabilitation evaluation. The method comprises the following steps: S1, carrying out edge calculation on the data, S3, transmitting the data subjected to edge calculation to a cloud server for deep modeling analysis of gait and balance parameters, S4, carrying out abnormal mode identification and comparison after parameter analysis, S5, uploading the analyzed data after comparison to a decision application layer, S6, transmitting each parameter and a corresponding processing scheme to a doctor end for a doctor to check, and S5, carrying out data processing. The method has the advantages that through full-link innovation of multi-mode lightweight acquisition, edge cloud hierarchical processing, double-model intelligent diagnosis, reinforcement learning dynamic optimization and visual remote decision, central nervous rehabilitation evaluation extends to a daily life scene from a laboratory, and core breakthrough of precision improvement, efficiency multiplication and personalized enhancement is achieved.

Described herein are compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with increased transduction enrichment in the central nervous system, brain, and / or spinal cord. The rAAV compositions described herein encapsidate a transgene, such as a therapeutic nucleic acid. The rAAV capsid and capsid proteins described herein comprise a sequence that bind to the TEK receptor tyrosine kinase (TEK) protein and / or tissue factor pathway inhibitor (TFPI) protein to facilitate crossing the blood-brain barrier. Gene therapy using the rAAVs is described. Also described are methods of treating brain-, spinal-, and central nervous system-related diseases and conditions.

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

An improved method of treating cancers with engineered T cells is described.

There are disclosed phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the disclosed compounds.

The invention discloses a macrophage-polymer lipid nanoparticle composite drug delivery system, a preparation method thereof and application of the macrophage-polymer lipid nanoparticle composite drug delivery system in cryptococcus infection resistance. According to the drug delivery system, alpha-linolenic acid (ALA), high molecular weight chitosan oligosaccharide (HCOS) and amphotericin B (AmB) are used as raw materials to construct nanoparticles AmB-PLHNs, the nanoparticles are loaded in macrophages through the phagocytosis of the macrophages, and the AmB-PLHNs (at) M1 is constructed. AmB is a common medicine for clinically treating Cn infection, but has the problems of toxic and side effects on kidney and incapability of being transferred into the center. The AmB-PLHNs (at) M1 carries AmB-PLHNs to be transferred into the brain according to the blood-brain barrier penetrating characteristic of M1 type macrophages, and the brain entering efficiency of the medicine is improved. By combining the phagocytosis of macrophages on cryptococcus, the inflammation immune regulation function of the macrophages and the bacteriostatic action of the drug-loaded nanoparticles, the drug-loaded nano-particles are used for treating Cn central infection, and the toxic and side effects of AmB are reduced.

The present disclosure provides double stranded oligonucleotides, compositions, and methods relating thereto. The present disclosure encompasses the recognition that structural elements of double stranded oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and / or internucleotidic linkages) or patterns thereof, and / or stereochemistry (e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages), and / or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, Ago2 loading, thermal stability, in vivo stability, delivery to tissues and into cells, etc. The present disclosure also provides methods for treatment of diseases, e.g., hepatic diseases, central nervous system (CNS) diseases, etc., using provided double stranded oligonucleotide compositions, for example, in RNA interference.

The disclosure provides methods for the for treatment of psychosis, such as schizophrenia, or depression (such as bipolar depression) and / or anxiety, comprising administering to a patient in need thereof, (i) a 5-HT2A or 5-HT2A / D2 receptor ligand, for example a substituted heterocycle fused gamma-carboline as described herein, in free, pharmaceutically acceptable salt or prodrug form, and (ii) a nitric oxide donor, separately (sequentially or simultaneously), or in combination (e.g., in a fixed dose combination).

The invention provides a cyclic peptide used for treating, improving or preventing nervous system injury of mammals or diseases or pains caused by the injury, neurodegenerative diseases, anxiety or epilepsy or used as a neuronal protective agent, a conjugate containing the cyclic peptide, a pharmaceutical composition containing the cyclic peptide or the conjugate and application of the cyclic peptide and the conjugate.

Medical devices for accessing the central nervous system, as well as making and using medical devices, are disclosed. An example medical device may include an expandable access sheath having a proximal end region and a distal end region. The expandable access sheath may be designed to shift between a first configuration and an expanded configuration. The expandable access sheath may include a tubular body having one or more axial support members disposed along the tubular body. The medical device may include an expansion member designed to shift the expandable access sheath between the first configuration and the expanded configuration.

The invention provides a deuterated etomidate derivative as well as a preparation method, an intermediate and application thereof. Particularly, the invention relates to a deuterated etomidate derivative shown in a general formula I ', a preparation method and an intermediate of the deuterated etomidate derivative, a pharmaceutical composition containing the deuterated etomidate derivative, and application of the deuterated etomidate derivative or the pharmaceutical composition of the deuterated etomidate derivative as a GABBA receptor agonist in preparation of drugs in the field of central nervous systems.

The present disclosure generally relates to methods and formulations for treating central nervous system (CNS) disorders. The present disclosure involves intranasal delivery of at least one antioxidant compound, allowing for effective treatment of a central nervous system disorder such as traumatic brain injury or stroke.

The invention relates to a phenylpropanoid compound as well as a preparation method and application thereof, in particular to a phenylpropanoid compound extracted from pleione bulbus pseudobulb as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention provides a method for preparing 10 new compounds from pleione bulbocodioides pseudobulb as a raw material for the first time, systematically evaluates the anti-neuroinflammation activity of pleione bulbocodioides pseudobulb, and clarifies the application of pleione bulbocodioides pseudobulb in development and treatment of central nervous system diseases. According to the invention, abnormally activated BV-2 microglial cells induced by LPS (Lipopolysaccharide) are adopted, and the NO release amount is taken as an index, so that the effect of the compound 1-10 on inhibiting excessive activation of the microglial cells is preliminarily evaluated. The result shows that the novel compounds 1-10 can inhibit the release of LPS-induced BV-2 microglial cell NO. Therefore, the compound prepared in the invention can be applied to development of drugs for treating central nervous system diseases.

The present invention relates to compositions and methods for treating neurodegenerative conditions using GLP-1r agonists. In certain embodiments, long-acting GLP-1r agonists have neuroprotective and disease modifying effects on the central nervous system.